# Introduction to the EU Regulatory Framework

REGULATIONS

David McCoubrey Regulatory Affairs Lead Almac Group





# Objectives

- 1) Regulatory procedures in Europe
- 2) Overview of Centralised Procedure
  - Main features
  - Submission requirements
  - Timelines
  - Procedural options
- 3) EU Orphan Medicinal Product Designations





# **European Union**

- 28 Member States
- 24 official national languages
- Population of 512 million
- Plus three additional EEA countries
  - Norway, Iceland and Liechtenstein





# EU Marketing Authorisation Procedures

There are four different routes to obtaining a Marketing Authorisation in the EU/EEA

- 1) Centralised Procedure
  - One application assessed by the European Medicines Agency
  - Results in one Marketing Authorisation valid in all EU/EEA Member States





# EU Marketing Authorisation Procedures

#### 2) Decentralised Procedure (DCP)

- An application is made to a number of EU/EEA States
- The assessment is carried out by one Member State (the Reference Member State)
- The authorisation is agreed with the other Member States (the Concerned Member States)





### EU Marketing Authorisation Procedures

#### 3) Mutual Recognition Procedure (MRP)

- An existing authorisation in one EU/EEA State is "mutually recognised" in a number of other EU/EEA States
- 4) National Procedure
  - A single application to an individual EU/EEA State





# MA Application Submission Strategy

Product type may influence EU submission route

- Mandatory for Centralised
  - New active substances for:
    - Oncology, Diabetes; Neurodegenerative, Autoimmune and Viral disorders; AIDS
  - Biotech products
  - Advanced Therapy Medicinal Products
    - Gene Therapy
  - Orphan Medicinal Products




# MA Application Submission Strategy

- Optional for Centralised
  - New active substances
  - Significant therapeutic, scientific or technical innovation, or in the interest of patients

8

- Certain paediatric products
- Generics or hybrids of Centralised products
- Conditional/Exceptional/PRIME/Accelerated procedures
  - Mostly only available via the Centralised route



the dife the star tile and

# **Centralised Procedure**





# Output of EU Centralised Review

Licence: One European Marketing Authorisation

Product Name: One name

Prescribing Info:

Identical Summary of Product Characteristics (SPC) and Identical Package Leaflet (PL) each in all EU official languages





# Centralised Procedure - Who does what?

- European Medicines Agency (EMA) in London
  - Coordinates the scientific evaluation
  - Utilises the existing scientific resources of Member States







# Centralised Procedure - Who does what?

- Committee for Medicinal Products for Human use (CHMP)
  - Scientific Committee of the EMA
  - Perform scientific review and provide a scientific opinion
  - One representative / 28 Member States + Norway and Iceland (Each EU Member State has an alternate/back-up member)
  - Up to five co-opted members with specific areas of expertise





# Centralised Procedure - Who does what?

- Rapporteur and Co-rapporteur
  - Members of the CHMP
  - Review the application and prepare assessment report(s) for the CHMP
- EU Commission in Brussels
  - Issues EU Commission Decision ('Licence') based on the Scientific Opinion
  - Legally binding to all Member States



ommission





# Key Information for Submission

- Applicant: Must be registered in EU/EEA
  - Provide proof of establishment
- Application form: Names of key personnel
  - Qualified Person for Pharmacovigilance
  - Scientific Service
- Drug substance/product manufacturing sites
  - Including EU Batch Testing and Batch Release Site(s)
- Risk Management Plan






## Key Information for Submission

- Labelling Mock-Ups
  - English mock-up and Multi-lingual mock-up (i.e. a worst-case mock-up) of outer and immediate packaging in each strength and container type in the smallest pack size
- Package Leaflet and User Testing Report
  - Optional at the time of initial MAA submission (at the latest with the Day 121 responses)
- CTD structure
  - eCTD submission format is mandatory



# Centralised Procedure Overview




 Legal requirement for CHMP Opinion within 210 days (not including validation and clock stop periods)






# Pre-submission



- Activities in advance of the dossier submission
- They start at least seven months before the submission date
- Eligibility request
- Letter of intent to submit
- Pre-submission meeting








- Electronic submission via the eSubmission Gateway
- Technical validation
- Regulatory and administrative validation
- 13 working days timeline but potential for delays






# **Primary Evaluation**



- Day 1 Start of Procedure
- Day 80 Receipt of initial assessment report by applicant
- Day 100 CHMP receives comments from committee members
- Day 120 Formal CHMP overview and list of questions sent to applicant



# First Clock Stop




- Day 120 Clock stops
- Applicant's responses expected within 3 months
- Includes revised English SPC, PL and pack labelling texts
- Day 121 Clock restarts






#### Secondary Evaluation



- Day 140 English product information review by EMA/QRD
- Day 157 Joint assessment report received by applicant
- Day 170 CHMP receives comments from committee members
- Day 180 List of outstanding issues adopted by CHMP




# Second Clock Stop



- Day 180 Clock stops
- Applicant's written responses expected within one month
- EMA decide if oral explanation is also required
- Day 181 Clock restarts and oral explanation meeting (if needed)



# Final Evaluation




 Day 181 to Day 210 - Final draft of English SPC, PL and labelling to be submitted by applicant





# **Opinion / Decision**



- By Day 210 CHMP adopts opinion and CHMP assessment report issued (CHMP opinions are based on majority voting)
- By Day 215 Product information in all EU languages (plus Icelandic and Norwegian) to be submitted by applicant
- Day 229 Member States send comments on translations
- Day 235 Final translations to be submitted by applicant
- Day 277 EU Commission Decision issued



# Specimens and Samples


- Specimens
  - Sales presentation of the product
    - Packaging and leaflet
  - Required to be submitted:
    - Before product is marketed
    - If number of languages used increases
- Samples
  - Drug product or ingredients
  - Required to be submitted:
    - Only on request during the assessment



### Centralised Procedure: Practical Timelines

26


Average number of days for centralised procedures - positive opinions (2012-2016)<sup>1</sup>





# Centralised Procedure: Practical Timelines

#### **EITHER:** Total duration ~14 months





#### Accelerated Assessment

- CHMP opinion in 150 days instead of 210 days
- EU equivalent of Priority Review in the US
- Justification based on major public health interest
  - Unmet needs
  - Therapeutic innovation
  - Major impact on medical practice





# Priority Medicines (PRIME) Scheme

- Supports the development of medicines that target an unmet medical need
  - The request is made based on preliminary clinical evidence

79

- EU equivalent of 'Breakthrough Therapy Designation' in the US
- Gives early engagement with the EMA
- Eligibility criteria are those of the accelerated assessment



# **Conditional Approval**

- Additional clinical data required but benefit to public health of immediate availability outweighs risk
- Can apply to:
  - Products for seriously debilitating or life-threatening diseases
  - Orphan designated medicinal products
- Valid for one year on a renewable basis
  - Required to complete ongoing or new studies
  - Once the studies are provided it can become a 'normal' MA



# Exceptional Circumstances Approval

- Comprehensive data <u>cannot</u> be provided e.g.
  - Extremely rare indications
  - Against medical ethics to collect data
- The MA may be granted subject to specific obligations e.g. additional studies or advice in Product Information
- Reviewed annually to assess the risk-benefit balance
- Will <u>not</u> normally lead to the completion of a full dossier and become a 'normal' MA





# **Orphan Designated Products**

- Medicines for serious rare diseases
  - Application to EMA for designation
- Procedural and marketing benefits
  - Mandatory access to centralised procedure
  - Eligible for Conditional Marketing Authorisation
  - Extended marketing exclusivity
- Financial benefits
  - Lower fees (further reductions available for Small and Medium-sized Enterprises)



# Summary of Centralised Procedure

- One Application, One Evaluation, One Authorisation
- EU-wide authorisation (plus Liechtenstein, Norway and Iceland) that is binding and identical in all Member States
- Set timelines
  - Scientific opinion in 210 days (plus clock stops)
  - Authorisation about two months later
- Options for innovative products
  - PRIME Scheme/Accelerated Assessment
  - Conditional Approval
  - Exceptional Circumstances Approval



# Questions...

# Thank you

